MedTrace Logo

Study of Comparing of With and Without Sequential Therapy of S-1

NCT05813015 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2023-04-14

No results posted yet for this study

Summary

The goal of this single arm clinical trial is to learn about sequential S-1 adjuvant therapy in patient wich locally advanced gastric cancer. The main question it aims to answer is:

• The efficacy and safety of S-1 adjuvant therapy, following D2 radical surgery and DS(Docetaxel + S-1) adjuvant chemotherapy.

All patients with locally advanced gastric cancer will received D2 radical surgery, 6 cycles of DS chemotherapy, and sequential S-1 chemotherapy up to 1 year postoperation.

Conditions

  • Locally Advanced Gastric Adenocarcinoma
  • Chemotherapy Effect

Interventions

DRUG

Docetaxel

Docetaxel 40mg/m2，every 21 days，6 cycles.

DRUG

Tegafur-Gimeracil-Oteracil

S-1 40-60mg/m2，p.o, BID, day 1-14, till 1 year postoperation.

Sponsors & Collaborators

  • Zhejiang University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-28
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05813015 on ClinicalTrials.gov